The Week in Review: M&A, Partnerships and Earnings

Beijing Yu Sheng Tang Pharma signed a MoU to purchase 70% of Nihon Seiyaku Kogyo for $7.6 million; Lilly contributed to Zhejiang BetaPharma’s latest fund raising and will co-develop drug candidates; a Johnson & Johnson subsidiary will build an R&D Oncology Center with Tianjin Medical University Cancer Hospital; Genzyme established a partnership with Tianjin Joint Academy of Biotechnology and Medicine; Boehringer Ingelheim will use M&A to increase its presence in the OTC sector; Roche Diagnostics has produced revenue increases of close to 50% per year; WuXi PharmaTech (药明康德) reported Q1 revenues rose 36% to $80.6 million; Mindray Medical announced Q1 revenues rose a modest 9% to $145.8 million; and Medpace Reference Labs said its new laboratories in Beijing and Mumbai received international accreditation. More details… Stock Symbols: (HK: 1141) (NYSE: LLY) (NYSE: JNJ) (NSDQ: GENZ) (VX: ROG) (NYSE: WX) (NYSE: MR)